Orphan Drug Approvals — June 16, 2026

Merck Sharp & Dohme secured two label expansions for its flagship oncology franchise—PEMBROLIZUMAB (KEYTRUDA) and BELZUTIFAN (WELIREG)—signaling execution capability and potentially broadening patient populations in key indications.

Hoffmann-La Roche received a label expansion for ALECTINIB HYDROCHLORIDE (ALECENSA), the standard-of-care for ALK-positive non-small cell lung cancer, likely broadening its addressable patient population and extending revenue durability.

PEMBROLIZUMAB (KEYTRUDA, Merck Sharp & Dohme) faces increasing competition from biosimilar PD-1 inhibitors and next-generation PD-(L)1 agents, which may erode incremental label expansion benefits.

ALECTINIB HYDROCHLORIDE (ALECENSA, Hoffmann-La Roche) faces pipeline competition from second-generation ALK inhibitors and potential combination therapies that could narrow its market share.

BELZUTIFAN (WELIREG, Merck Sharp & Dohme) expansion could unlock a larger patient population in VHL-related tumors or clear cell renal cell carcinoma, driving incremental revenue in a niche but durable market.

Merck Sharp & Dohme's ability to secure label expansions for both KEYTRUDA and WELIREG in close succession signals strong regulatory execution and a potentially healthy oncology pipeline.

All three approvals in this period were label expansions for established oncology assets, reflecting a sector-wide strategy of extending product life cycles through incremental indication changes rather than novel NME launches.

{"entity"=>"PEMBROLIZUMAB (KEYTRUDA) - Merck Sharp & Dohme", "reason"=>"Label expansion adds incremental market access, but KEYTRUDA faces IRA Medicare negotiation starting year 11 (biologic status) and PD-1 competition.", "trigger"=>"IRA negotiation timeline for biologics (year 13 from approval); first negotiation year likely 2034"}

{"entity"=>"BELZUTIFAN (WELIREG) - Merck Sharp & Dohme", "reason"=>"WELIREG is a small molecule; subject to IRA negotiation starting year 9 from approval (original NDA approval date needed to determine exposure).", "trigger"=>"Small molecule IRA negotiation year 9 from original FDA approval date"}

{"entity"=>"ALECTINIB HYDROCHLORIDE (ALECENSA) - Hoffmann-La Roche", "reason"=>"ALECENSA faces competitive pressure from next-gen ALK inhibitors and potential biosimilar erosion; label expansion may provide temporary support.", "trigger"=>"Phase 3 readouts for lorlatinib or repotrectinib in ALK+ NSCLC"}